GSK2256098
- Generic Name
- GSK2256098
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C20H23ClN6O2
- CAS Number
- 1224887-10-8
- Unique Ingredient Identifier
- R7O0O4110G
- Background
GSK2256098 is under investigation in clinical trial NCT02523014 (Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas).
- Associated Conditions
- -
- Associated Therapies
- -
A Study of GSK2256098 and Trametinib in Advanced Pancreatic Cancer
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2015-04-28
- Last Posted Date
- 2022-11-01
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 16
- Registration Number
- NCT02428270
- Locations
- π¨π¦
Juravinski Cancer Center, Hamilton, Ontario, Canada
π¨π¦London Regional Cancer Centre, London, Ontario, Canada
π¨π¦The Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada
A Dose Escalation Study to Assess Safety of GSK2256098 (FAK Inhibitor) in Combination With Trametinib (MEK Inhibitor) in Subjects With Advanced Solid Tumors
- First Posted Date
- 2013-09-10
- Last Posted Date
- 2019-07-12
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 34
- Registration Number
- NCT01938443
- Locations
- π¬π§
GSK Investigational Site, Newcastle upon Tyne, United Kingdom
Study of a Focal Adhesion Kinase Inhibitor in Subjects With Solid Tumors
- First Posted Date
- 2010-06-07
- Last Posted Date
- 2017-05-11
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 74
- Registration Number
- NCT01138033
- Locations
- π¬π§
GSK Investigational Site, Newcastle upon Tyne, United Kingdom
Phase I Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of GSK2256098 in Healthy Volunteers
- First Posted Date
- 2009-10-16
- Last Posted Date
- 2017-06-14
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 38
- Registration Number
- NCT00996671
- Locations
- π¦πΊ
GSK Investigational Site, Melbourne, Victoria, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
Β© Copyright 2024. All Rights Reserved by MedPath